Statin Use and Cardiovascular Disease in HIV
|
|
- Coral Todd
- 6 years ago
- Views:
Transcription
1 Statin Use and Cardiovascular Disease in HIV Steven K. Grinspoon, MD Professor of Medicine Harvard Medical School Boston, Massachusetts FLOWED: 04/18/16 Los Angeles, California: April 25, 2016 Statin Use and Cardiovascular Disease in HIV Steven Grinspoon, M.D. Professor of Medicine Harvard Medical School IAS USA April 25, 2016 Slide 2 of 36 Financial Relationships With Commercial Entities Dr Grinspoon has served as a consultant to Navidea Biopharmaceuticals, Theratechnologies, Merck & Co, Inc, and Gilead Sciences, Inc. He has received grants and research support to his institution from Gilead Sciences, Inc, Kowa Pharmaceuticals, and Theratechnologies. (Updated 04/25/16) Slide 3 of 36 1
2 Learning Objectives After attending this presentation, participants will be able to: Describe the current epidemiology of cardiovascular disease (CVD) in HIV Describe the unique pathophysiology of CVD in HIV Describe the potential utility and limitations of statin use to prevent CVD in HIV Slide 4 of 36 Most Epidemiological Studies Suggest that Rates of CVD in HIV are: 6% 1. Equal to that seen in non HIV 38% 50% 6% 2. 10% higher % higher % higher Slide 5 of 36 Current Status of CVD Prevention in HIV Even as rates of death and mortality related to HIV have decreased with use of more potent ART, CVD rates, remain increased among HIV patients and are a leading cause of morbidity and mortality There is limited understanding of the mechanisms and treatment strategies for CVD in HIV No large scale primary CVD prevention strategy has been tested in HIV Slide 6 of 36 2
3 Effect Size of MI or CHD in HIV vs. non HIV 5/2/2016 CVD Risk in HIV-Infected Patients is Beyond That Predicted by Traditional Risk Factors Slide 7 of In the VACS cohort, the HR of MI was 1.48 in HIV vs. non-hiv veterans after adjusting for FRS, comorbidities, and substance use (95% CI ). (Freiberg, 2013) 7% Which of the Following is Not a Common Feature of Coronary Plaque in HIV Patients? 19% 1. Eccentric high risk fatty plaque lesions 74% 2. Inflamed plaque 3. Heavily calcified plaque Slide 8 of 36 Increased Traditional Risk Factors Account for Only a Portion of CVD Risk in HIV A 12 Events Per 1000 PYs RR 1.75 P< Hypertension Diabetes Dyslipidemia 0 HIV Non-HIV HIV+ non-hiv+ DM, HTN, and dyslipidemia, though increased, accounted for 25% of excess risk Newer studies suggest importance of genetics, inflammation and immune dysfunction, as non traditional risk factors Slide 9 of 36 Triant JCEM 2007, Rotger Clin Infect Dis
4 Aortic TBR by PET 5/2/2016 HIV: a State of Immune Activation and Suppression HIV Infection CD4+ T cells Persistent viral infection Microbial translocation Viral reactivation (CMV) and coinfection (HCV) Chronic activation of T cells and monocytes Endothelial cell activation Slide 10 of 36 Acute MI Adapted from Hsue JID 2012 Immune Activation Relates to Novel Atherosclerotic Phenotype in HIV In the general population, MI does not typically result from gradual expansion of subclinical coronary plaque, but rather from rupture of vulnerable high risk plaque in 75% of cases Recent studies in HIV+ patients without known CVD demonstrate that atherosclerotic plaques are indeed: Inflamed Non-calcified, high risk morphology features (vulnerable) Associated with immune activation markers Slide 11 of 36 Increased Arterial Inflammation in HIV 3.0 Control HIV p = p = Slide 12 of 36 HIV FRS -Matched Controls CVD Controls Subramanian JAMA
5 Aortic (TBR) 5/2/2016 Arterial Inflammation Linked to Immune Activation in HIV Slide 13 of ρ=0.53; P-value< Natural Log of scd163 (ng/ml) Inflamed High Risk Plaque Identified by FDG Composed of Activated Macrophages Slide 14 of 36 Rudd Circulation 2002 Increased Rates of Atherosclerosis in HIV by Coronary CT Angiography Slide 15 of 36 Control HIV P value Presence of plaque 34% 59% 0.02 Mean plaque volume (µl) Agatson Score 0 (0, 9.9) 0 (0,17.9) 0.29 Segments with plaque Non-calcified segments 0.46± ±1.57 <0.05 Calcified segments 0.29± ± Any stenosis > 70% 0% 6.5% 0.06 Young HIV-infected men and matched controls Baseline FRS, FH CHD, and smoking rates similar Similar data observed from the MACS cohort Lo AIDS 2010; Post Annals
6 % of subjects with high risk morphology plaque 5/2/2016 Increased High Risk Morphology Plaque in HIV Patients LOW ATTENUATION PLAQUE (LAP) Mean minimal attenuation < 40 Hounsefield Units RC A POSITIVELY REMODELED Plaque segment / (PR) PLAQUE reference segment > 1.05 Slide 16 of 36 RC A Naghavi Circ 2003, Schoenhanger Circ 2000 &JACC 2001; Zanni AIDS 2013 A New Paradigm for Atherogenesis in HIV Persistent Viral Replication Microbial Translocation T-cell activation Monocyte Activation RCA Slide 17 of 36 High Risk Plaque Inflammation Slide 18 of 36 Current Challenges in Preventing and Treating CHD in HIV Understanding the optimal timing and use of ART to maximize effects on immune function and minimize metabolic effects Identifying patients with disease: current risk identification strategies are not adequate Developing a safe and effective strategy for primary prevention, especially for those not identified by current algorithms, but with substantial subclinical disease Developing an intervention that addresses both traditional and immune-related risk factors 6
7 SMART and START- Effects on CVD SMART- Randomized trial of continuous vs. intermittent ART guided by CD4 count (begun when <250 and stopped when >350). Stringent viral suppression reduced AIDS and CVD events. START- Randomized trial of immediate vs. delayed ART in naïve HIV patients with CD4 > 500 (vs. initiation at CD4 < vs. 350). Earlier initiation reduced AIDS events but not CVD events. Slide 19 of 36 SMART NEJM 2006; START NEJM 2015 Statins Have the Unique Potential to Work in HIV Because: 0% 1. They reduce triglycerides 3% 2. They improve glucose simultaneously with lipids 3% 3. They lower LDL 4. They lower LDL and may have anti-inflammatory effects 94% Slide 20 of 36 Slide 21 of 36 Potential Interventions For CVD in HIV Traditional Risk Modification Strategies - Antihypertensive - Antidiabetic -ASA -Statins Immune/Inflammatory Modulators -ART -CCR5 Antagonists - IL Antagonists - Methotrexate - Statins 7
8 Statin Effects on CVD in non HIV Population In a meta-analysis of 26 studies with 170,000 patients, statins were shown to reduce events by 22% per 39 mg/dl lowering in LDL Slide 22 of 36 CTT Lancet ACC/AHA Statin Guidelines Unclear how these guidelines pertain to HIV Patients Need for a discussion between patients and providers Need for more data Slide 23 of 36 Stone Circulation 2013 Many HIV Patients with High-Risk Plaque would not Receive Recommendation for Statin by 2013 Guidelines: CHD risk underestimated by traditional risk scores Slide 24 of 36 Zanni AIDS
9 Statins Reduce Vascular Events in Non HIV Patients with Low LDL and Increased CRP Events/100p-y: Placebo: 1.36 Rosuva: 0.77 HR 0.56 LDL was reduced 47 mg/dl, and should have resulted in a HR of 0.73 based on LDL lowering alone, according to CTTC meta-analysis. Instead JUPITER showed a HR of 0.56, greater than expected based on LDL lowering alone Slide 25 of 36 Ridker N Engl J Med 2008; CTTC Lancet 2010 Statins Address Both Traditional and Immune Risk Factors in HIV LDL Lowering: Statins lower LDL by similar amounts in patients with and without HIV: (HIVinfected: -26.2%; HIV-uninfected: -26.9%) Dampening of Immune Activation: Decrease monocyte activation reflected in decreased circulating levels of scd14 and the macrophage-derived phospholipase Lp-PLA2 Slide 26 of 36 Silverberg Ann Int Med 2009, McComsey CROI 2013, Funderburg JAIDS epub Statins are Generally Safe and Well-Tolerated in HIV Absolute rates of grade 3 or 4 adverse effects on liver and muscle low (Silverberg Ann Int Med 2009) Despite immune suppressant effects, no adverse effects on viral replication (Moncunill AIDS 2005, Negredo AIDS 2006) Slide 27 of 36 9
10 Percent Change in Noncalcified Plaque Absolute Change in Direct LDL (mg/dl) (ng/ml) 5/2/2016 Newer Statins May Not Increase Glucose and Not Interact with PIs Drug PI Interaction Effects on Glucose LDL Lowering and Dose Pravastatin (40 mg/d) mg/dl, -25% Atorvastatin (20 to 40 mg/d) + +/- -38 mg/dl, -29% Rosuvastatin (10 mg/d) mg/dl -28% Pitavastatin (4 mg/d)* mg/dl, -28% Pitavastatin metabolized primarily by glucoronidation. Minimally metabolized by CYP3A. No known interactions with antiretroviral therapy no dose limitations. Included in 2013 ACC/AHA guidelines as a recommended moderate dose statin. *Among dyslipidemic patients with high starting cholesterol levels. Slide 28 of 36 Sponseller CROI 2014, Aberg Endo 2013, Eckard JID 2014, Stone JACC Statin Effects on Coronary Artery Plaque in HIV p =.009 p = p <.0001 p < p =.005 p =.005 Placebo Atorvastatin Change in Lp-PLA Placebo Atorvastatin Placebo Atorvastatin Slide 29 of 36 Decreasing non-calcified plaque in proximal left anterior descending (LAD) coronary artery in patient on atorvastatin for 12 months. Lo CROI 2015, Lancet HIV 2015 Need for a Large RCT to Inform Clinical Practice HIV patients with low traditional risk scores are at increased risk for CVD with subclinical plaque and inflammation It is unknown if statins will prevent CVD and should be recommended for the HIV population Though largely well tolerated in small studies, there are no data from large RCTs in HIV investigating efficacy and tolerability How will statins uniquely work in HIV? LDL lowering Effects on inflammatory pathways Slide 30 of
11 100+ Sites Across US, Thailand and Canada Opened April Slide 31 of 36 REPRIEVE Schema Asymptomatic HIV patients with no history of CVD and ASCVD < 10% N=6500, avg. 4-5 yrs 3 visits/year Placebo R Lifestyle Advice Pitavastatin Screening and Consent Randomization Intervention N=800, 2 yrs Mechanistic Study Coronary plaque, vascular Inflammation, immune activation Mechanistic Primary Endpoint CVD Death MI Unstable Angina TIA & Stroke Arterial Revasc PAD Clinical Primary Endpoint Slide 32 of 36 Endpoints Time to first Major Adverse Cardiovascular Event (MI, Stroke, Angina, Revascularization, PAD, CVD death) Secondary Endpoints AIDS events Non AIDS events (liver, kidney, DM) Relationship of immune function and LDL to MACE response Safety Slide 33 of 36 11
12 Mechanistic Substudy Objectives: To determine: Effects on high risk coronary plaque Effects on immune function in relationship to plaque Green + Red: Noncalcified Plaque Volume: 115 mm 3 Red: Low Attenuation Plaque Volume: 28 mm 3 Slide 34 of Novelty First major CVD prevention trial in HIV Largest study to date focused on HIV-related CVD; will inform standard of care Represents a new paradigm of long-term prevention trial for chronic co-morbidities Partnership between NHLBI, NIAID and Office of AIDS Research to fund an important HIV study Slide 35 of 36 Conclusions and Future Directions Traditional and non traditional risk factors contribute to increased CVD risk in HIV, which manifests as inflamed, noncalcified high risk plaque in association with immune activation Modulation of traditional and nontraditional risks is necessary to prevent CVD in HIV Statins may be an effective strategy to prevent CVD in HIV and should be tested in large trials to determine optimal practice patterns Slide 36 of 36 12
The Role of Aspirin in HIV & Aging: Pro-Standpoint
The Role of Aspirin in HIV & Aging: Pro-Standpoint Virginia Triant Massachusetts General Hospital 6 th International Conference on HIV and Aging October 6, 2015 None Disclosures Questions for Debate Should
More informationDr Currier received a research grant to UCLA from Theratechnologies (Updated 02/20/17)
Management of Long-Term Complications of HIV Disease With a Focus on Cardiovascular Disease Judith S. Currier, MD Professor of Medicine University of California Los Angeles Los Angeles, California FORMATTED:
More informationCardiovascular Complications of HIV and Its Treatment
Cardiovascular Complications of HIV and Its Treatment FORMATTED: 11/6/15 Marshall J. Glesby, MD, PhD Professor of Medicine, Healthcare Policy and Research Weill Cornell College of Medicine New York, New
More informationCardiovascular Disease Management in HIV Infection
Slide 1 of XX Cardiovascular Disease Management in HIV Infection Turner Overton, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama Learning Objectives After attending this
More informationIntersection of HIV & NCD s: Clinical Implications
Intersection of HIV & NCD s: Clinical Implications Mosepele Mosepele MD, MSc University of Botswana Faculty of Medicine Botswana-Harvard AIDS Institute Partnership & Harvard School T.H. Chan School of
More informationHIV and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Implications
HIV and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Implications Matthew J. Feinstein, MD, MSc Assistant Professor of Medicine Northwestern University Feinberg School of Medicine Chicago,
More informationLandmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549
2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes
More informationPerspective Cardiovascular Complications of HIV Infection
Perspective Cardiovascular Complications of HIV Infection HIV-infected individuals are at increased risk for cardiovascular events. Widely used cardiovascular disease (CVD) risk calculators to determine
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationHIV AND CEREBROVASCULAR DISEASE: AN INTERSECTION OF EPIDEMICS
HIV AND CEREBROVASCULAR DISEASE: AN INTERSECTION OF EPIDEMICS Felicia C. Chow, MD, MAS University of California, San Francisco Departments of Neurology and Medicine (Infectious Diseases) September 26,
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationDo Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus
Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationManagement of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?
Perspective Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin? Current guidelines for managing cholesterol to reduce cardiovascular disease (CVD)
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationPitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age
Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age Craig A. Sponseller, Masaya Tanahashi, Hideki Suganami,
More informationTen Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?)
Prevention and Treatment of CVD in Older Patients with Diabetes and Pre Diabetes: Hypertension and Dyslipidemia ASP Workshop on Diabetes Mellitus and Cardiovascular Disease in Older Adults Pentagon City
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationImmune Activation: Impact on Outcomes Peter W. Hunt, MD. Associate Professor of Medicine University of California San Francisco
Immune Activation: Impact on Outcomes Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco 10y Decreased Life Expectancy in Older HIV+ Adults in Modern ART Era ~9y shorter
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationDisclosures. Outline. Outline. Lipids, Statins and HIV: Topics in Clinical Management
Disclosures Lipids, Statins and HIV: Topics in Clinical Management Medical Management of AIDS & Hepatitis December 10, 2016 Research grant support from Gilead Sciences for work in East Africa related to
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationDisclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?
Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationDYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES
DYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES SATURDAY/4:30-5:30PM ACPE UAN: 0107-9999-17-249-L01-P 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists:
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationHIV e infarto miocardico: un problema dimenticato?
HIV e infarto miocardico: un problema dimenticato? Leonardo Calza Clinica di Malattie Infettive, Policlinico S.Orsola-Malpighi, Università degli Studi di Bologna CVD and HIV disease. The current issues
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationCoronary Artery Calcification
Coronary Artery Calcification Julianna M. Czum, MD OBJECTIVES CORONARY ARTERY CALCIFICATION Julianna M. Czum, MD Dartmouth-Hitchcock Medical Center 1. To review the clinical significance of coronary heart
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationHIV & Cardiovascular Disease Update
HIV & Cardiovascular Disease Update Virginia A. Triant Massachusetts General Hospital 13 th Annual National Conference on HIV/AIDS & Aging September 29, 2017 None Disclosures Learning Objectives Outline
More informationSex-Specific Mechanisms of Coronary Heart Disease Risk among Women Aging with HIV
7 th International Workshop on HIV and Women February 12, 2017 Sex-Specific Mechanisms of Coronary Heart Disease Risk among Women Aging with HIV Markella V. Zanni, MD Assistant Professor of Medicine, Harvard
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationCardiac CT for Risk Assessment: Do we need to look beyond Coronary Artery Calcification
Cardiac CT for Risk Assessment: Do we need to look beyond Coronary Artery Calcification Matthew Budoff, MD, FACC, FAHA Professor of Medicine Director, Cardiac CT Harbor-UCLA Medical Center, Torrance, CA
More informationSTATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP
STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC Director of Preventative Cardiology CGH Medical Center, Sterling, Illinois
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationHans Strijdom SA Heart Meeting November 2017
Hans Strijdom SA Heart Meeting November 2017 HIV-infection and ART, but not high sensitivity CRP, are associated with markers of vascular function: Results from the Western Cape cohort of the EndoAfrica
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals How to Comply with ASCVD Guidelines and HIV thrombosis Risk Reduction Virginia A. Triant Massachusetts General Hospital
More informationUsing Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly
Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationCombining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging
Combining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging Daniel S. Berman, MD Director, Cardiac Imaging Cedars-Sinai Heart Institute Professor of Medicine and Imaging Cedars-Sinai
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More information